Translational Development Acquisition Corp.
TDACU- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0001926599
No open-market purchases or sales by Translational Development Acquisition Corp. insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $365.9K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −2 vs. previous quarter
- 3
- 13F valueReported value at the end of Q2 2026
- $365.9K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TDACU, Q2 2026
No superinvestor reported holding TDACU at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Translational Development Acquisition Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 29, 2026 (view filing) | May 27 | 2 days | Hoffman Michael BChairman and CEO | PPurchaseClass A ordinary shares | +53.4K | $0.79 | +$42.2K | –53.4K after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Translational Development Acquisition Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Clear Street Group Inc. | 12,344 | $139.6K | 0.00% | +12,344 | New |
| Flow Traders U.S. LLC | 11,659 | $132.0K | 0.01% | −2,428−17.2% | Reduced |
| UBS Group AG | 8,338 | $94.3K | 0.00% | −10.0% | Reduced |